Silverback Therapeutics, Inc. (SBTX)
Chart Events
Performance Outlook
| Previous Close | 38.66 |
| Open | 39.42 |
| Bid | 29.47 x 800 |
| Ask | 38.23 x 900 |
| Day's Range | 36.93 - 39.73 |
| 52 Week Range | 24.22 - 63.41 |
| Volume | 93,961 |
| Avg. Volume | 244,508 |
| Market Cap | 1.329B |
| Beta (5Y Monthly) | N/A |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 52.25 |
- Business Wire
Silverback Therapeutics to Present SBT6290 Preclinical Data at the AACR 2021 Annual Conference
Silverback Therapeutics, Inc. (Nasdaq: SBTX) ("Silverback"), a clinical-stage biopharmaceutical company leveraging its proprietary ImmunoTAC technology platform to develop systemically delivered, tissue-targeted therapeutics for the treatment of cancer, chronic viral infections and other serious diseases, will present preclinical data on its second product candidate, SBT6290, at the American Association of Cancer Research (AACR) 2021 Annual Conference, taking place virtually April 10-15. The data highlight the ability of SBT6290, a systemically administered Nectin4-directed TLR8 ImmunoTAC product candidate, to selectively activate myeloid cells in the tumor microenvironment, a promising approach to overcome resistance mechanisms associated with most current immunotherapies.
- Business Wire
Silverback Therapeutics Reports Fourth Quarter and Full Year 2020 Financial Results and Recent Corporate Updates
Silverback Therapeutics, Inc. (Nasdaq: SBTX) ("Silverback"), a clinical-stage biopharmaceutical company leveraging its proprietary ImmunoTAC technology platform to develop systemically delivered, tissue targeted therapeutics for the treatment of cancer, chronic viral infections, and other serious diseases, today reported financial results and provided a corporate update for the fourth quarter and full year ended December 31, 2020.
- Business Wire
Silverback Therapeutics Announces the Appointment of Dr. Maria Koehler to its Board of Directors
Silverback Therapeutics, Inc. (Nasdaq: SBTX) ("Silverback"), a clinical-stage biopharmaceutical company leveraging its proprietary ImmunoTAC technology platform to develop systemically delivered, tissue targeted therapeutics for the treatment of cancer, chronic viral infections, and other serious diseases, today announced the appointment of Maria Koehler, M.D., Ph.D. to Silverback’s Board of Directors.
